10-Q: InMed Pharmaceuticals Q3 2026 Financial Results

InMed Pharmaceuticals reports Q3 2026 financial results, highlighting the wind-down of its BayMedica commercial segment and a focus on its pharmaceutical pipeline.

Summary

• Net loss for the three months ended March 31, 2026, was $2.97 million, compared to $2.12 million in the same period of 2025.
• Cash and cash equivalents were $5.16 million as of March 31, 2026.
• The company is winding down its BayMedica commercial operations, expected to be completed by June 30, 2026.
• Management expects current cash to fund operations into the fourth quarter of calendar 2026.
• The company received a Nasdaq delisting notice regarding minimum bid price requirements on March 27, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk situation due to the going concern warning, the loss of the only revenue stream, and the threat of Nasdaq delisting.

Positives

• New preclinical data for INM-901 shows significant reduction in neuroinflammation in human brain organoid models.
• Strategic pivot to focus exclusively on high-potential pharmaceutical drug candidates.
• Successful reduction of finance expenses compared to the prior year.

Negatives

• Net loss increased to $2.97 million for the quarter.
• Cash position declined from $10.74 million at June 30, 2025, to $5.16 million at March 31, 2026.
• Accumulated deficit reached $124 million.
• Ongoing arbitration regarding a patent license matter with a third party.

Risks

• Substantial doubt regarding the ability to continue as a going concern.
• Potential delisting from Nasdaq if minimum bid price is not regained.
• Material adverse impact from the wind-down of the only revenue-generating segment.
• Uncertainty regarding the outcome of the Patent License Matter arbitration.
• Need for additional capital to fund operations beyond Q4 2026.

Future Outlook

The company plans to focus exclusively on its pharmaceutical pipeline, specifically INM-901 for Alzheimer's and INM-089 for dry AMD, targeting IND filings and clinical trials. It expects to fund operations into Q4 2026 and is actively seeking additional capital or strategic transactions.

Management Comments

• Management emphasizes the de-risking of the INM-901 program through successful human brain organoid studies.
• The company is actively exploring strategic opportunities to address liquidity and long-term viability.

Industry Context

StockSavvy.ai notes that the company is undergoing a significant transition from a hybrid commercial/R&D model to a pure-play drug development firm, a common trend for small-cap biotech companies facing regulatory headwinds in the cannabinoid sector.

Comparison to Industry Standards

• The company's cash runway is limited compared to larger, well-capitalized biotech peers.
• The pivot to focus on NCEs for neurodegenerative diseases aligns with current industry trends in CNS drug development.

Corporate Governance

Legal Proceedings

• Arbitration with a third-party licensor regarding a patent license agreement, involving claims of approximately $3.4 million in past payments and $2.3 million in future annual minimums.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises.
• Employees in the BayMedica segment are subject to severance as part of the wind-down.
• Creditors and partners may be impacted by the restructuring.

Next Steps

• Complete wind-down of BayMedica by June 30, 2026.
• Conduct pre-IND meeting for INM-901 in Q3 2026.
• Plan pre-IND meeting for INM-089 in Q4 2026.
• Monitor and address Nasdaq minimum bid price compliance.

Key Dates

Recommendation

The combination of a going concern warning, the loss of the only revenue-generating segment, and the threat of Nasdaq delisting presents significant downside risk for investors.

Keywords

InMed Pharmaceuticals, INM, Biotech, Alzheimers, Cannabinoid, Nasdaq, Going Concern